Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mood Disorders in Children and Adolescents Clear all
Completed No phase listed Observational Accepts healthy volunteers

White Matter in Pediatric Bipolar Disorder: A DTI Study

NCT00391235
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
6 Years to 13 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2010 · Synced Jul 24, 2026, 4:36 AM EDT
Enrolling by invitation No phase listed Observational

Youth Depression and Suicide Research Network

NCT04572321
View directory record Official record
Conditions
Depression, Suicide, Suicidal Ideation, Suicide, Attempted, Depressive Disorder, Depressive Symptoms, Depressive Episode, Depression and Suicide, Depression, Teen, Depression, Anxiety
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 20 Years
Enrollment
5,000 participants
Timeline
2020 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 24, 2026, 4:36 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jul 24, 2026, 4:36 AM EDT
Terminated Phase 4 Interventional Results available

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

NCT00592683
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
Aripiprazole, fish oil, Placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

NCT00090311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Scottsdale, Arizona • Riverside, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
17
States / cities
San Diego, California • Altamonte Springs, Florida • Libertyville, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

NCT00265330
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
41
States / cities
Scottsdale, Arizona • San Diego, California • Aurora, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Jul 24, 2026, 4:36 AM EDT
Completed No phase listed Observational

Cortical Excitability and Inhibition in MDD

NCT01718730
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Interventions
Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Jul 24, 2026, 4:36 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder

NCT02811133
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Anxiety
Interventions
Inositol
Drug
Lead sponsor
Ronald M. Glick, MD
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Integrated Treatment for Youth With Mood Disorders

NCT03800303
View directory record Official record
Conditions
Mood Disorders in Children and Adolescents
Interventions
Family-based treatment
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 18 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Jul 24, 2026, 4:36 AM EDT
Terminated Phase 4 Interventional

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

NCT02623504
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Orlando, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 24, 2026, 4:36 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00529789
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Dothan, Alabama • Chandler, Arizona • El Centro, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders

NCT02357290
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Open-label Treatment with N-Acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 24, 2026, 4:36 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

NCT01371721
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 24, 2026, 4:36 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional

Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents

NCT00036582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

NCT00723450
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lamictal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 24, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional

Child Bipolar Network Ketogenic Diet Approach to Bipolar Disorder in Adolescents

NCT06920940
View directory record Official record
Conditions
Bipolar Disorder (BD), Bipolar Disorder NOS, Bipolar Disorder I or II, Bipolar Spectrum Disorder, Adolescents
Interventions
Ketogenic Therapy
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 24, 2026, 4:36 AM EDT